ArticleMolecules (Basel, Switzerland)2025
Extracts, Fractions, and Subfractions from Purple-Orange Sweet Potato (
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Source to Utilization: A Review of Influencing Factors and Safety Assessment for High-Value Utilization of Sweet Potato (Foods (Basel, Switzerland) · 2026Review
- Comparative Phytochemical Analysis ofMolecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous research has shown that fractions outperformed extracts in pharmacological activity and safety. This study assessed the total phenol and flavonoid content, as well as antioxidant and xanthine oxidase inhibitory (XOI) activities, of purple-orange sweet potato extracts, fractions, and subfractions. Using UV-visible spectrophotometry, the leaves showed the highest values for total phenol, flavonoid, 2,2-diphenyl-1-picrylhydrazyl (DPPH), Ferric Reducing Antioxidant Power (FRAP), Cupric Ion Reducing Antioxidant Capacity (CUPRAC) assays, and XOI activity. The sequential extraction of the leaves yielded ethyl acetate extract as the most potent, with a yield of 10.4%, a DPPH assay result of 511.212 ± 0.416 mg ascorbic acid equivalent antioxidant capacity (AEAC)/g, and XOI activity of 45.192 ± 4.981 mg allopurinol equivalent xanthine inhibitory capacity (AEXIC)/g. CF5 had the greatest DPPH assay (158.475 ± 0.170 mg AEAC/g), FRAP assay (86.849 ± 0.048 mg AEAC/g), CUPRAC assay (1008.892 ± 1.620 mg AEAC/g), and XOI activity (6.062 ± 1.730 mg AEXIC/g) values. Subfraction CSF3 from fraction CF5 was analyzed using UPLC-MS/MS and revealed the presence of compounds such as cholest-4-en-3-one, 4-hydroxy-6-[2-(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl) ethyl] oxan-2-one, tangeritin, 4-methyl benzophenone, benzophenone, (+)-ar-turmerone, 4-methoxycinnamic acid, and ricinine. This study was the first to report xanthine oxidase inhibitory activity in allopurinol equivalence. The leaves of the purple-orange sweet potato showed potential as a source of natural antioxidants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.